JYNT vs. PYXS, UTMD, CDXS, NYXH, SENS, APPS, CDXC, CHRS, ZURA, and AKBA
Should you be buying Joint stock or one of its competitors? The main competitors of Joint include Pyxis Oncology (PYXS), Utah Medical Products (UTMD), Codexis (CDXS), Nyxoah (NYXH), Senseonics (SENS), Digital Turbine (APPS), ChromaDex (CDXC), Coherus BioSciences (CHRS), Zura Bio (ZURA), and Akebia Therapeutics (AKBA).
Joint (NASDAQ:JYNT) and Pyxis Oncology (NASDAQ:PYXS) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, dividends, valuation, profitability, community ranking, media sentiment and analyst recommendations.
Joint received 260 more outperform votes than Pyxis Oncology when rated by MarketBeat users. However, 80.00% of users gave Pyxis Oncology an outperform vote while only 62.50% of users gave Joint an outperform vote.
In the previous week, Pyxis Oncology had 3 more articles in the media than Joint. MarketBeat recorded 5 mentions for Pyxis Oncology and 2 mentions for Joint. Joint's average media sentiment score of 1.89 beat Pyxis Oncology's score of 0.43 indicating that Joint is being referred to more favorably in the media.
Joint has higher revenue and earnings than Pyxis Oncology. Joint is trading at a lower price-to-earnings ratio than Pyxis Oncology, indicating that it is currently the more affordable of the two stocks.
Joint currently has a consensus target price of $22.00, suggesting a potential upside of 37.16%. Pyxis Oncology has a consensus target price of $8.80, suggesting a potential upside of 132.19%. Given Pyxis Oncology's stronger consensus rating and higher possible upside, analysts clearly believe Pyxis Oncology is more favorable than Joint.
Pyxis Oncology has a net margin of 0.00% compared to Joint's net margin of -9.24%. Joint's return on equity of 3.94% beat Pyxis Oncology's return on equity.
76.9% of Joint shares are owned by institutional investors. Comparatively, 39.1% of Pyxis Oncology shares are owned by institutional investors. 30.2% of Joint shares are owned by company insiders. Comparatively, 9.3% of Pyxis Oncology shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Joint has a beta of 1.58, indicating that its stock price is 58% more volatile than the S&P 500. Comparatively, Pyxis Oncology has a beta of 1.45, indicating that its stock price is 45% more volatile than the S&P 500.
Summary
Joint beats Pyxis Oncology on 10 of the 17 factors compared between the two stocks.
Get Joint News Delivered to You Automatically
Sign up to receive the latest news and ratings for JYNT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding JYNT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
